Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?

The outcome and quality of life of chronic myeloid leukemia (CML) patients has remarkably changed with the treatment of tyrosine kinase inhibitors (TKIs). Currently, hematopoietic stem cell transplantation (HSCT) is considered mainly as a third line salvage therapy in cases of TKIs resistance or int...

Descripción completa

Detalles Bibliográficos
Autores principales: Barak, Avital F., Bonstein, Lilach, Lauterbach, Roy, Naparstek, Elizabeth, Tavor, Sigal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269798/
https://www.ncbi.nlm.nih.gov/pubmed/22593820
http://dx.doi.org/10.4081/hr.2011.e29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269798/
https://www.ncbi.nlm.nih.gov/pubmed/22593820
http://dx.doi.org/10.4081/hr.2011.e29

Ejemplares similares